Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sonoma Pharmaceuticals (SNOA) Inventory (2016 - 2025)

Sonoma Pharmaceuticals has reported Inventory over the past 15 years, most recently at $4.0 million for Q4 2025.

  • For Q4 2025, Inventory rose 27.87% year-over-year to $4.0 million; the TTM value through Dec 2025 reached $4.0 million, up 27.87%, while the annual FY2025 figure was $3.2 million, 6.57% up from the prior year.
  • Inventory for Q4 2025 was $4.0 million at Sonoma Pharmaceuticals, up from $3.9 million in the prior quarter.
  • Over five years, Inventory peaked at $4.0 million in Q4 2025 and troughed at $2.5 million in Q3 2021.
  • A 5-year average of $3.0 million and a median of $2.9 million in 2022 define the central range for Inventory.
  • Biggest five-year swings in Inventory: tumbled 37.51% in 2021 and later skyrocketed 43.04% in 2025.
  • Year by year, Inventory stood at $2.9 million in 2021, then fell by 1.04% to $2.8 million in 2022, then rose by 3.72% to $3.0 million in 2023, then increased by 6.36% to $3.1 million in 2024, then increased by 27.87% to $4.0 million in 2025.
  • Business Quant data shows Inventory for SNOA at $4.0 million in Q4 2025, $3.9 million in Q3 2025, and $3.8 million in Q2 2025.